Cardinal Health (NYSE:CAH - Get Free Report) had its price target raised by equities researchers at Barclays from $275.00 to $320.00 in a report released on Wednesday, Benzinga reports. The brokerage currently has an "overweight" rating on the stock. Barclays's price objective would indicate a potential upside of 14.58% from the stock's previous close.
A number of other research analysts also recently weighed in on the stock. Argus raised their target price on shares of Cardinal Health from $264.00 to $309.00 and gave the company a "buy" rating in a research report on Thursday, November 12th. Morgan Stanley boosted their price target on shares of Cardinal Health from $265.00 to $286.00 and gave the stock an "overweight" rating in a research report on Friday, October 30th. Leerink Partners set a $292.00 price objective on shares of Cardinal Health in a research note on Tuesday, August 11th. UBS Group raised their price objective on Cardinal Health from $280.00 to $295.00 and gave the company a "buy" rating in a report on Friday, October 16th. Finally, JPMorgan Chase & Co. lifted their target price on Cardinal Health from $260.00 to $286.00 and gave the company a "neutral" rating in a research report on Tuesday, November 10th. One research analyst has rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Cardinal Health presently has a consensus rating of "Moderate Buy" and a consensus target price of $290.13.
Get Our Latest Research Report on CAH
Cardinal Health Stock Down 1.6%
NYSE:CAH opened at $279.29 on Wednesday. The company has a market cap of $64.55 billion, a P/E ratio of 36.13, a price-to-earnings-growth ratio of 2.17 and a beta of 0.53. Cardinal Health has a twelve month low of $180.45 and a twelve month high of $286.29. The business has a 50 day moving average price of $245.68 and a two-hundred day moving average price of $225.95.
Cardinal Health (NYSE:CAH - Get Free Report) last posted its quarterly earnings data on Thursday, November 5th. The company reported $3.26 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.94 by $0.32. The company had revenue of $67.51 billion for the quarter, compared to the consensus estimate of $66.67 billion. Cardinal Health had a net margin of 0.71% and a negative return on equity of 102.72%. The firm's revenue was up 5.5% compared to the same quarter last year. During the same period last year, the company earned $2.55 earnings per share. As a group, analysts anticipate that Cardinal Health will post 12.97 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Cardinal Health
Hedge funds and other institutional investors have recently bought and sold shares of the business. BlackRock Inc. bought a new position in shares of Cardinal Health during the 2nd quarter worth about $6,293,115,000. Wellington Management Group LLP increased its position in Cardinal Health by 247.5% in the 2nd quarter. Wellington Management Group LLP now owns 14,860,271 shares of the company's stock valued at $3,530,206,000 after buying an additional 10,584,119 shares in the last quarter. Bank of America Corp DE bought a new stake in Cardinal Health in the 2nd quarter valued at about $689,066,000. Legal & General Group Plc acquired a new position in Cardinal Health during the 2nd quarter worth approximately $438,870,000. Finally, Pacer Advisors Inc. raised its stake in Cardinal Health by 14.7% during the 1st quarter. Pacer Advisors Inc. now owns 1,565,131 shares of the company's stock worth $330,728,000 after buying an additional 200,021 shares during the period. Institutional investors own 87.17% of the company's stock.
Cardinal Health Company Profile
(
Get Free Report)
Cardinal Health is a healthcare services and products company that distributes pharmaceuticals and medical supplies. Its customers include pharmacies, hospitals, surgery centers, physician offices and other healthcare providers. The company's businesses include pharmaceutical distribution and specialty services, as well as the sourcing and distribution of medical and surgical products. Its offerings support areas such as specialty medications, medication management and supply-chain operations. Cardinal Health traces its roots to a wholesale business founded in Ohio in 1971 and later expanded into pharmaceutical distribution.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Cardinal Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cardinal Health wasn't on the list.
While Cardinal Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.